Novo Nordisk released Wegovy in pill form, marking the first FDA-approved GLP-1 weight-loss medication available orally rather than by injection. The pill form is expected to cost significantly less than the injectable version, ranging from $25 to $149-$299 per month depending on dosage and insurance coverage.
In a study, participants taking the pill demonstrated approximately 17% weight loss if they remained on treatment. The trial showed average body weight loss of 13.6% over 64 weeks for active drug participants compared to 2.2% for placebo participants. Those who stayed longer in the trial averaged 16.6% weight loss. Ed Cinca, senior vice president of Marketing and Patient Solutions at Novo Nordisk, stated, “We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them.”
Population health context and caution
In Grays Harbor County, approximately 10% of nearly 78,000 residents are diabetic, with 36.5% considered obese. According to the USDA, nearly 90% of healthcare spending goes toward treating chronic disease linked to diet and lifestyle, with more than 70% of American adults overweight or obese and nearly one in three adolescents having prediabetes.
Grays Harbor County Public Health Director Mike McNickle urged caution, noting the study showed average weight loss of 13.6% to 16.6% but raised concerns about long-term outcomes after discontinuation. A January 2025 study from Washington University found GLP-1 drugs associated with benefits to cognitive and behavioral health but also increased risks for pancreatitis and kidney conditions. Additionally, research indicates that 35% to 45% of GLP-1 weight loss is not fat but “lean mass” including muscle and bone, and that 50% to 75% of patients discontinue treatment within one year, leading to weight rebound.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.thedailyworld.com/news/drug-maker-releases-glp-1-in-cheaper-pill-form/